Dave Duplay sits down with John L. Lehr, President & CEO of the Parkinson's Foundation, to talk about the challenges faced by those affected by Parkinson's disease, and what the Parkinson's Foundation is doing to help raise awareness and find a cure.
Health360: HealthTalk: John L. Lehr | Parkinson's Awareness Month
New initiative “Live Well. Do Tell.” will encourage the PD community to improve conversations about Parkinson’s symptoms among the circle of care, including people with Parkinson’s. The Parkinson’s Foundation is part of the initiative’s steering committee.
"The Parkinson’s Foundation provides information including news about the disease, information about upcoming events, insight into the latest research, and education about what to expect."
Insights from a new study — by the University of Cambridge in the United Kingdom — about the role of calcium in brain cells' signaling mechanisms brings us closer to understanding the causes of Parkinson's disease, including statistics from the Parkinson's Foundation's Parkinson's Outcomes Project.
Michael S. Okun, MD, Parkinson’s Foundation National Medical Director is quoted in this article about signs your body gives you as a harbinger for possible disease or illness.
Tomorrow edition interviews Peter Schmidt, Ph.D., is Senior Vice President, Chief Research & Clinical Officer, at the Parkinson’s Foundation. Dr. Schmidt discusses selective vulnerability in PD, replicating the disease in a lab and discusses PD clinical trial processes.
John L. Lehr, CEO of the Parkinson’s Foundation, believes that Neil Diamond's public discussion of having Parkinson's will further push use of the Parkinson's Foundation Helpline.
Dr. James Beck interview on Neil Diamond's retirement & Parkinson's
"My thanks goes out to my loyal and devoted audiences around the world. You will always have my appreciation for your support and encouragement," Neil Diamond said after di
Parkinson's disease is a neurodegenerative disorder that can cause tremors, slowness of movement and other symptoms.
James Beck, Chief Scientific Officer, is quoted in response to pharmaceutical funding pulling out from specific research: "Other pharmaceutical companies are also weighing this option and if the biggest of the bunch decides to exit the party, it might have a ripple effect on the others."
"The fear is that this becomes a trend," said James Beck, the Chief Scientific Officer at the Parkinson’s Foundation. “Other pharmaceutical companies are also weighing this option and if the biggest of the bunch decides to exit the party, it might have a ripple effect on the others,” he told Newsweek.